Sensus Healthcare Q2 revenue misses estimates as unit sales fall
SRTS•Analyst coverage and price target
The current average analyst rating on the shares is buy, with 4 strong buy or buy recommendations, no hold and no sell or strong sell.
The average consensus recommendation for the advanced medical equipment and technology peer group is buy. Wall Street's median 12-month price target for Sensus Healthcare Inc is $6.00, about 91.7% above its Aug. 12 closing price of $3.13.
Outlook and reimbursement backdrop
Sensus said it expects to recognize revenue from eight units in Q3 because of the delayed financing approval.
The company also said CMS proposed a 26% increase in the hospital-based SRT delivery code, which could improve the reimbursement outlook. Sensus said it remains focused on delivering strong second-half 2026 performance.
Q2 revenue and EBITDA miss estimates
Sensus Healthcare said second-quarter revenue fell sharply and missed analyst expectations, while adjusted EBITDA loss widened year over year, reflecting lower unit sales and product mix.
| Metric | Beat/Miss |
|---|
